MX2013000877A - Aplicación de dihidroxiclorinas beta-funcionalizadas para tfd. - Google Patents

Aplicación de dihidroxiclorinas beta-funcionalizadas para tfd.

Info

Publication number
MX2013000877A
MX2013000877A MX2013000877A MX2013000877A MX2013000877A MX 2013000877 A MX2013000877 A MX 2013000877A MX 2013000877 A MX2013000877 A MX 2013000877A MX 2013000877 A MX2013000877 A MX 2013000877A MX 2013000877 A MX2013000877 A MX 2013000877A
Authority
MX
Mexico
Prior art keywords
pdt
chlorins
another embodiment
precursors
dihydroxy
Prior art date
Application number
MX2013000877A
Other languages
English (en)
Other versions
MX353394B (es
Inventor
Daniel Aicher
Volker Albrecht
Christian B W Stark
Arno Wiehe
Susanna Grafe
Original Assignee
Biolitec Pharma Marketing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolitec Pharma Marketing Ltd filed Critical Biolitec Pharma Marketing Ltd
Publication of MX2013000877A publication Critical patent/MX2013000877A/es
Publication of MX353394B publication Critical patent/MX353394B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona métodos para obtener compuestos biológicamente activos que se pueden usar como fotosensibilizadores para aplicaciones de diagnóstico y terapéuticas, particularmente para la TFD del cáncer, infecciones y otras enfermedades hiperproliferativas, diagnósticos de fluorescencia y tratamiento de TFD de una indicación no tumoral tal como artritis, enfermedades inflamatorias, infecciones virales o bacterianas, trastornos dermatológicos, oftalmológicos o urológicos. Una modalidad de la presente invención consiste de un método para sintetizar las diceto-clorinas como precursores. En otra modalidad más, estos precursores se convierten a hidroxi y dihidroxi-clorinas B-funcionalizadas. Otra modalidad es para proporcionar compuestos anfifílicos con una afinidad de membrana más alta y eficacia de TFD mejorada. Otra modalidad consiste en la formulación del isómero deseado en una formulación liposomal para ser inyectada, evitando los efectos indeseables como la precipitación en el sitio de inyección o la farmacocinética demorada de los sistemas de tetrapirrol.
MX2013000877A 2010-07-22 2011-08-12 Aplicación de dihidroxiclorinas beta-funcionalizadas para tfd. MX353394B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36670710P 2010-07-22 2010-07-22
PCT/US2011/047576 WO2012012809A2 (en) 2010-07-22 2011-08-12 APPLICATION OF β-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT

Publications (2)

Publication Number Publication Date
MX2013000877A true MX2013000877A (es) 2013-07-03
MX353394B MX353394B (es) 2018-01-11

Family

ID=45497505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000877A MX353394B (es) 2010-07-22 2011-08-12 Aplicación de dihidroxiclorinas beta-funcionalizadas para tfd.

Country Status (8)

Country Link
EP (1) EP2870159B1 (es)
JP (1) JP2013532664A (es)
CN (1) CN103097390B (es)
BR (1) BR112013001576A2 (es)
IL (1) IL224381B (es)
MX (1) MX353394B (es)
PL (1) PL2870159T3 (es)
WO (1) WO2012012809A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013001577B1 (pt) * 2010-07-22 2021-05-04 Biolitec Unternehmensbeteiligungs Ii Ag conjugados de carboidrato e dihidroxiclorina
WO2013015774A1 (en) 2011-07-22 2013-01-31 Biolitec Pharma Marketing Ltd Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy
CN103995045A (zh) * 2014-05-29 2014-08-20 武汉矽感科技有限公司 离子迁移谱仪用于检测乐果和马拉硫磷残留的用途及方法
US9722103B2 (en) 2015-06-26 2017-08-01 Sunpower Corporation Thermal compression bonding approaches for foil-based metallization of solar cells
CN104940950B (zh) * 2015-07-09 2017-11-28 武汉大学 一种肿瘤靶向多肽光敏剂键合物
CN111196819B (zh) * 2018-11-16 2023-03-28 中国科学院上海药物研究所 一类d-a-d型苯并吡嗪类化合物及制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648485A (en) * 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
FR2877943B1 (fr) * 2004-11-16 2008-09-05 Univ De Coimbra Nouveaux derives de porphyrine, notamment chlorines et/ou bacteriochlorine, et leurs applications en therapie photodynamique
EP2350058B1 (en) * 2008-09-18 2018-10-24 biolitec Unternehmensbeteiligungs II AG Novel method and application of unsymmetrically meso-substituted porphyrins and chlorins for pdt
JP6041360B2 (ja) * 2011-07-22 2016-12-07 バイオリテック ウンターネーメンスベタイリグンクス ツヴァイ アクツィエンゲゼルシャフト 抗菌性光線力学療法のための、糖−置換ジヒドロキシ−クロリン及びβ−官能化クロリン

Also Published As

Publication number Publication date
WO2012012809A3 (en) 2012-05-18
EP2870159A2 (en) 2015-05-13
MX353394B (es) 2018-01-11
EP2870159B1 (en) 2017-06-28
WO2012012809A2 (en) 2012-01-26
BR112013001576A2 (pt) 2016-07-19
CN103097390A (zh) 2013-05-08
JP2013532664A (ja) 2013-08-19
EP2870159A4 (en) 2015-08-12
PL2870159T3 (pl) 2018-01-31
IL224381B (en) 2018-03-29
CN103097390B (zh) 2017-03-08

Similar Documents

Publication Publication Date Title
MX2013000877A (es) Aplicación de dihidroxiclorinas beta-funcionalizadas para tfd.
WO2011130753A3 (en) Functionalized nano- and micro-materials for medical therapies
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
EP2350058A4 (en) NOVEL METHOD AND APPLICATION OF NON-SYMMETRICALLY SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY
WO2009050506A3 (en) Combination 059
EP3501546A3 (de) Cystein-wirkstoff konjugate und ihre verwendung
UA112425C2 (uk) ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MY168791A (en) Carbamate compounds and of making and using same
WO2007134245A3 (en) Elastin-like polymer delivery vehicles
EP3818991A3 (en) Compositions and methods for treating diseases
WO2010057112A3 (en) Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
WO2009147201A3 (en) Anti-inflammatory agents
EP1971338B8 (en) Combination of zd6474 and pemetrexed
WO2011098518A3 (en) Delivery of immunoglobulin variable domains and constructs thereof
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
NZ601559A (en) Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine
WO2005092385A3 (en) Combination therapy of azd2171 and a taxane
WO2010141143A3 (en) Engineered avirulent bacteria strains and use in medical treatments
WO2021113851A3 (en) Peptide docking vehicle for targeted nucleic acid delivery
RU2010145383A (ru) Способ лечения острого панкреатита
UA109904C2 (uk) Комбінована терапія для шкірних розладів

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG

FG Grant or registration